By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Alere has licensed the worldwide marketing rights to VitaPath Genetics' spina bifida risk assessment assay, the companies announced Wednesday.

The deal also gives Alere the right to develop with Foster City, Calif.-based VitaPath additional product line extensions mainly focusing on fetal health.

Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The partially reinstated US travel ban leaves space for uncertainty for researchers, Nature News says.

Researchers find a number of traits differ by sex and could affect mouse model studies, according to Reuters.

Tweaking the skin microbiome could help address some skin conditions, the New York Times reports.

In PNAS this week: DNA methylation profiles of tumor tissue, gene dynamics in prokaryotes, and more.